Metraipolis › archive › dc_ffe72bf4b185

Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system — Europe PMC PMID:38724914

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/38724914
DOI
10.1186/s12879-[numero omesso]-4
License (as archived)
solo-consultazione
Archived
2026-10-08T14:30:08.255Z
SHA-256 of the archived text
df5994a49d36932b0730ef1c521594ffd343887e7f7245e6cb4bba34df50d9d7
Stable URL of this page
https://metraipolis.com/documento/dc_ffe72bf4b185

How to cite

Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system — Europe PMC PMID:38724914 — Europe PMC (en), https://europepmc.org/article/MED/38724914 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ffe72bf4b185 (Metraipolis archive dc_ffe72bf4b185, sha256 df5994a49d36932b0730ef1c521594ffd343887e7f7245e6cb4bba34df50d9d7)
BibTeX
@misc{dcffe72bf4b185,
  title = {Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system — Europe PMC PMID:38724914},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/38724914},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ffe72bf4b185; sha256 df5994a49d36932b0730ef1c521594ffd343887e7f7245e6cb4bba34df50d9d7},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/38724914. Agents can read the archived copy with the MCP tool read_document.